Condition
Complicated Skin and Skin Structure Infections
Total Trials
5
Recruiting
0
Active
0
Completed
4
Success Rate
80.0%-7% vs avg
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
80.0%
-6.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
75%
3 of 4 completed with results
Key Signals
3 with results80% success
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 4 (1)
Trial Status
Completed4
Terminated1
Trial Success Rate
80.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT01072539CompletedPrimary
Study Evaluating The Safety And Effectiveness In Subjects With Tigecycline Treatment
NCT02288234Completed
Telavancin Observational Use Registry (TOUR)
NCT01104662Phase 4TerminatedPrimary
Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment
NCT01128530Phase 2CompletedPrimary
Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)
NCT00683332CompletedPrimary
Post-Marketing Study Of The Safety Of Tygacil (Tigecycline)
Showing all 5 trials